ABOUT ETON

Eton Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative sterile injectable products utilizing the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway

OUR PORTFOLIO

Eton Pharmaceuticals, Inc.’s pipeline includes patented formulations of Corticotropin injection and Pentoxifylline injection, as well as numerous undisclosed injectable and ophthalmic products in late-stage development. All products in Eton Pharmaceuticals’s pipeline will be filed with the FDA under the 505(b)(2) regulatory pathway, and Eton anticipates filing its first New Drug Application in 2018.

Eton Pharmaceuticals Appoints Paul V. Maier to its Board of Directors

Sep 14, 2017

FULL STORY

Eton Pharma Appoints Dr. Norbert Riedel to its Board of Directors

September 7, 2017

FULL STORY

Eton Pharma Names Sean Brynjelsen Chief Executive Officer and Director

June 23, 2017

FULL STORY

Eton Pharma Announces $20 Million Series A Financing

June 20, 2017

FULL STORY

Imprimis Spins Off Eton Pharma To Challenge Pricey Pipelines Of Mallinckrodt, Endo

June 20, 2017

FULL STORY

©2017 by Eton Pharmaceuticals

21925 W. Field Pkwy, Suite 235
Deer Park, IL 60010